Technology Crossover Management X Ltd. purchased a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,653,566 shares of the company's stock, valued at approximately $4,762,000. GoodRx comprises 0.6% of Technology Crossover Management X Ltd.'s investment portfolio, making the stock its 6th biggest position. Technology Crossover Management X Ltd. owned approximately 0.48% of GoodRx as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in GDRX. Essential Partners LLC grew its position in shares of GoodRx by 375.4% in the first quarter. Essential Partners LLC now owns 14,304 shares of the company's stock valued at $28,000 after purchasing an additional 11,295 shares during the last quarter. Meridian Wealth Management LLC acquired a new position in shares of GoodRx during the 4th quarter worth about $29,000. SG Americas Securities LLC acquired a new position in shares of GoodRx during the 1st quarter worth about $29,000. Krilogy Financial LLC bought a new stake in GoodRx during the 1st quarter valued at approximately $33,000. Finally, Quarry LP bought a new stake in GoodRx during the 3rd quarter valued at approximately $33,000. 63.77% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
Several research analysts have commented on GDRX shares. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $4.00 price target on shares of GoodRx in a research report on Friday, August 7th. Wall Street Zen raised GoodRx from a "hold" rating to a "buy" rating in a research report on Saturday. Weiss Ratings upgraded shares of GoodRx from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, August 7th. Wells Fargo & Company boosted their target price on shares of GoodRx from $3.50 to $5.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Finally, Citigroup upped their target price on shares of GoodRx from $4.00 to $5.00 and gave the company a "buy" rating in a research note on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $4.14.
Get Our Latest Stock Analysis on GoodRx
GoodRx Stock Performance
GoodRx stock opened at $3.65 on Wednesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The stock has a fifty day moving average price of $3.07 and a two-hundred day moving average price of $2.61. GoodRx Holdings, Inc. has a 52-week low of $1.77 and a 52-week high of $5.81. The firm has a market capitalization of $1.25 billion, a P/E ratio of 91.27, a P/E/G ratio of 1.77 and a beta of 1.60.
GoodRx (NASDAQ:GDRX - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, meeting the consensus estimate of $0.08. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The company had revenue of $200.41 million for the quarter, compared to the consensus estimate of $193.23 million. During the same quarter in the previous year, the company earned $0.09 EPS. The firm's revenue for the quarter was down 1.3% compared to the same quarter last year. As a group, analysts anticipate that GoodRx Holdings, Inc. will post 0.16 EPS for the current fiscal year.
About GoodRx
(
Free Report)
GoodRx Holdings, Inc NASDAQ: GDRX operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.
In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
